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Abstract 
This study examined whether allelic status of the D2 dopamine receptor (DRD2) gene was 
associated with response to a selective serotonin reuptake inhibitor, paroxetine, in the 
treatment of posttraumatic stress disorder (PTSD). Sixty-three Caucasian war veterans with 
combat-related PTSD were treated with paroxetine for 8 weeks. Patients were assessed at 
baseline and at follow-up using the General Health Questionnaire-28 (GHQ). TaqI A DRD2 
alleles were determined by PCR. Before paroxetine treatment, patients with the DRD2 A1+ 
allele (A1A2 genotype) compared to those with the A1− allele (A2A2 genotype) had higher 
total GHQ psychopathological scores (P=0.040) and higher GHQ subscale scores for 
anxiety/insomnia (0.046), social dysfunction (P=0.033) and depression (P=0.011). In an 
intention-to-treat analysis, paroxetine was associated with significant improvement in total 
GHQ scores (P=0.014) and in the factor scores of social dysfunction (P=0.033), anxiety 
(P=0.009) and depression (P=0.026). Furthermore, there was a significant allele by time 
interaction on the social dysfunction scale, with A1+ allelic patients showing significant 
improvement in social functioning compared to A1− allelic patients (P=0.031), an effect 
independent of changes in depression or anxiety. This suggests changes in social 
functioning induced by paroxetine may be, in part, mediated via D2 dopamine receptors. 
The DRD2 A1 allele may prove to be a useful marker to assist clinicians in predicting which 
patients with PTSD are likely to obtain improvements in social functioning with paroxetine 
treatment.  
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Combat-related posttraumatic stress disorder (PTSD) is a highly debilitating condition with 
a chronic course. The quality of life of PTSD patients is frequently compromised by 
comorbid conditions such as social anxiety disorder, panic disorder, generalized anxiety 
disorder, dysthymia and major depressive disorder (Zatzick et al., 1997  ;   O’Toole et al., 
1998). Social, marital and vocational functioning are often impaired (Friedman et al., 1994). 
 
Selective serotonin reuptake inhibitors (SSRIs) are an effective treatment for a wide variety 
of psychiatric disorders. These include PTSD, depression, social phobia, and mixed anxiety 
and depressive states. Indeed, SSRIs are generally accepted to be the first line 
pharmacotherapy for PTSD (Hidalgo and Davidson, 2000  ;   Ballinger et al., 2000). 
Paroxetine is currently the most potent SSRI available. It is a weak inhibitor of 
noradrenaline uptake and has little affinity for dopaminergic systems (Bourin et al., 2001). 
 
Paroxetine is approved for use in all five anxiety disorders as well as in major depression 
(Wagstaff et al., 2002). It is an effective drug that is a well tolerated treatment for PTSD 
(Marshall et al., 2001  ;   Tucker et al., 2001). Additionally, paroxetine has beneficial effects 
on several important parameters of social functioning including harm avoidance, social 
dominance and social hostility, with changes in social dominance and social hostility 
occurring independently of improvements in anxiety/depression (Brody et al., 2000). This 
suggests that the physiological mechanisms involved in ameliorating social dysfunction are 
different from those involved in the anxiolytic and antidepressant actions of paroxetine. 
 
There is growing evidence that medication effects are frequently genetically mediated. 
Serotonin reuptake inhibition and subsequent changes in gene transcription produce 
upregulation or downregulation of receptors. This is responsible for the therapeutic actions 
of SSRIs (Stahl, 1999). However, a review of the literature on genetic predictors of response 
found no available studies on genetic markers that may assist clinicians in the selection of 
an antidepressant (for review, see   Nelson, 1999). 
 
The present study examined two hypotheses: (1) untreated PTSD patients with the DRD2 
A1 allele would report greater social dysfunction than patients without this allele and (2) the 
A1 allele would be associated with improvements in social functioning in patients following 
paroxetine treatment when compared to those without this allele. 
 
2. Experimental procedures 
Sixty-three unrelated male Caucasian patients with the diagnosis of PTSD were recruited for 
study. All subjects were Vietnam combat veterans who had served in the Australian armed 
forces. None were being treated with psychotropic medication. Patients were excluded from 
the study if they had a diagnosis of psychosis, bipolar disorder, obsessive compulsive 
disorder, organic brain syndrome, glaucoma, cardiac disease, or were being treated with 
anticoagulants or drugs affecting hepatic metabolism (Aropax® (Paroxetine) product 
information, 1999). 
 
Patients were assessed for PTSD by a consultant psychiatrist (BL) or a trainee psychiatrist 
(BK) using Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria. All 
met DSM-IV criteria for PTSD. Additionally PTSD caseness was confirmed with all 
patients exceeding the clinical cut-off score of 94 on the Mississippi Scale for combat-
related PTSD (Zatzick et al., 1997). The validity and reliability of the Mississippi scale are 
well established in veterans (Keane et al., 1988). Patients then underwent clinical history 
taking by a psychiatrist (BL), a trainee psychiatrist (BK) or by a clinical nurse (EP). 
Demographic data and ethnic background were also obtained. 
 
After initial assessment, patients were medically examined and then commenced on 20 
mg/day of paroxetine for the initial 2 weeks of the study. This was followed by a 40-mg/day 
dose for the remaining 6 weeks. Response to paroxetine commences after 1 week of 
treatment but does not exceed placebo until 2 weeks of therapy have been completed 
(Aropax® (Paroxetine) product information, 1999). 
 
The General Health Questionnaire-28 (GHQ) was administered at baseline (0–7 days on 
paroxetine) and at the end of treatment (8 weeks after commencement on paroxetine). This 
questionnaire measures four psychopathological factors particularly relevant to PTSD and 
its comorbid psychiatric conditions: somatic concerns (GHQ1), anxiety/insomnia (GHQ2), 
social dysfunction (GHQ3) and depression (GHQ4). The GHQ has been widely validated 
internationally as a means of detecting psychiatric caseness and is sensitive to change 
(Ormel et al., 1989). The GHQ has utility as a follow-up measure of veteran mental health 
following exposure to combat (Deahl et al., 1994) and is sensitive to changes in combat-
related PTSD symptoms (Ward, 1997). 
 
A 10-ml blood sample was drawn from each patient. Genomic DNA was extracted 
employing standard techniques and used as a template for determination of TaqI A DRD2 
alleles by the polymerase chain reaction (Grandy et al., 1993). The amplification of DNA 
was carried out using a Perkin-Elmer GeneAmp 9600 thermocycler. Approximately 500 ng 
of amplified DNA were digested with five units of TaqI restriction enzyme (New England 
Biolabs) at 65 °C overnight. The resulting products were separated by electrophoresis in a 
2.5% agarose gel containing ethidium bromide and visualized under ultraviolet light. Three 
genotypes are obtained: the A1A2 genotype is revealed by three fragments: 310, 180 and 
130 bp. The A2A2 genotype by two fragments: 180 and 130 bp. The A1A1 genotype is 
shown by the uncleaved 310-bp fragment. A1+ allelic subjects are those that either have the 
A1A1 or A1A2 genotype; A1− allelic subjects have the A2A2 genotype only. 
 
Patient assessments were conducted blind to their DRD2 allelic status. All adverse events 
were monitored and recorded. Drug compliance was checked by pill count. All participants 
provided written informed consent and were able to terminate treatment without prejudice. 
However, those terminating participation were asked to provide reasons for their 
withdrawal. Institutional ethics approval was obtained from the Greenslopes Private 
Hospital. 
 
Information coded from the interviews, GHQ and genotyping results were entered into a 
computer database. Nominal data were analyzed by Yates corrected 2-test and continuous 
data by ANOVA. P values ≤0.05 were considered statistically significant. P values >0.05 
but <0.10 were considered to be approaching a significant level. An intention-to-treat 
analysis was used to evaluate the trial. 
 
3. Results 
The 63 subjects recruited were all males. They had the following genotypes: A1A2 (A1+ 
allele), n=25; and A2A2 (A1− allele), n=38. In the present sample there were no subjects 
with the A1A1 genotype. This genotype distribution did not deviate from Hardy–Weinberg 
equilibrium (2=2.67, P=0.102). The mean age±S.E. of the 59 patients for whom data were 
available was 51.4 years±0.7 years. There was no significant difference in the ages of A1+ 
(51.1±0.8 years) and A1− (51.6±1.0 years) allelic subjects (F(1,57)=0.88, P=0.77). 
 
Of the 63 patients who entered the study, 18 (four A1+ and 14 A1− allele) discontinued 
paroxetine treatment for a variety of reasons. There was a trend for a greater number of A1− 
allelic subjects to discontinue treatment when compared to A1+ allelic participants (2=3.21, 
P=0.064). Amongst those who provided reasons for discontinuing the study, one A1+ and 
six A1− allelic subjects had adverse events relating to anxiety, insomnia, headache or 
tremor. In addition, one A1+ and two A1− allelic subjects experienced erectile dysfunction, 
decreased libido or delayed ejaculation. 
 
The 45 subjects who completed treatment were 51.8±0.8 years old. They had the following 
alleles: A1+, n=22; A1−, n=23. There was no significant difference in the ages of these A1+ 
(51.4±0.9 years) and A1− (52.2±1.4 years) allelic subjects (F(1,43)=0.27, P=0.61). 
 
As indicated earlier, 18 of the initial subjects dropped out of the study for a variety of 
reasons. The baseline GHQ total score of these subjects was 44.8±3.7 (mean±SD). In the 
remaining 45 subjects the GHQ total score was 48.0±2.5. There was no significant 
difference in the GHQ total score between those who dropped out and those who remained 
in the study (F(1,63)=0.55, P=0.46). 
 
Fig. 1 shows the baseline GHQ total and subscale scores of the 63 patients who entered the 
paroxetine treatment study based on the presence or absence of the DRD2 A1 allele. GHQ 
total score was significantly higher in A1+ compared to A1− allelic patients (F(1,62)=4.31, 
P=0.040). No significant difference was found in GHQ1 (somatic concerns) subscale score 
between these two allelic groups (F(1,62)=0.183, P=0.670). However, in A1+ compared to 
A1− allelic subjects, significantly higher subscale scores were found in GHQ2 
(anxiety/insomnia, F(1.62)=4.15, P=0.046), GHQ3 (social dysfunction, F(1.62)=4.77, 





Fig. 1. Baseline GHQ total scores and GHQ subscale scores of the 63 patients who entered paroxetine 
treatment based on the presence or absence of the DRD2 A1 allele. (a) P=0.040; (b) P=0.046; (c) P=0.033; (d) 
P=0.011. 
 
Fig. 2 shows the intention-to-treat baseline and treatment GHQ total scores of the 63 
patients. A significant improvement was found in the total patients during the course of 
paroxetine treatment (F=6.35, P=0.014). Fig. 2 also presents the baseline and treatment 
GHQ total scores of those patients based on their allelic status. The results showed no 
significant difference in improvement in the GHQ total score in A1+ patients compared to 





Fig. 2. Intention-to-treatment analysis of GHQ subscale scores at baseline and following paroxetine treatment 




Fig. 3 presents the intention-to-treat analysis results of the four GHQ subscale scores at 
baseline and after treatment. In the total patient group, there was a trend for GHQ1 (somatic 
concerns) subscale scores to improve over the course of treatment (F=3.641, P=0.061) but 
there was no difference between allele groups (F=0.538, P=0.466). GHQ2 (anxiety) 
subscale score was significantly reduced in the total patient group over the course of 
treatment (F=7.314, P=0.009).There was no significant difference between allele groups in 
changes in anxiety (F=1.641, P=0.205). There was also a significant improvement in GHQ3 
(social dysfunction) subscale score in the total patient group over the course of treatment 
(F=4.736, P=0.033). However, there was a significant difference between allele groups with 
A1+ allelic subjects experiencing significantly greater improvement than A1− allelic 
patients (F=4.903, P=0.031). Finally, GHQ4 (depression) subscale score revealed a 
significant improvement in the total patient group during treatment (F=5.191, P=0.026). No 












Fig. 3. Intention-to-treatment analysis of GHQ subscale scores at baseline and following paroxetine treatment 
based on the presence or absence of the DRD2 A1 allele. (a) P=0.009; (b) P=0.033; (c) P=0.031; (d) P=0.026. 
 
Whereas, as shown in Fig. 1, significantly higher baseline GHQ total score and its three 
subscale scores (GHQ2, GHQ3, GHQ4) were found in the A1+ compared to the A1− allelic 
groups, at the end of paroxetine treatment, no significant differences were found between 
these allelic groups in any of the GHQ scores measured: GHQ total (F(1,43)=0.001, 
P=0.99); GHQ1 (F(1,43)=1.5, P=0.23); GHQ2 (F(1,43)=0.14, P=0.71); GHQ3 (F(1,43)=1.1, 
P=0.30); GHQ4 (F(1,43)=2.5, P=0.12). 
 
4. Discussion 
The present open label trial confirms the effectiveness of paroxetine treatment in reducing 
psychopathological symptoms in Vietnam veterans with combat-related PTSD (Marshall et 
al., 1998 and Marshall et al., 2001     Zygmont et al., 1998  ,   Brady et al., 2000). This 
reduction in total symptoms measured was unrelated to patients’ DRD2 allelic status. 
 
At baseline, total psychopathology score was greater in DRD2 A1+ than in A1− allelic 
patients. In particular A1+ compared to A1− allelic individuals showed significantly higher 
levels of social dysfunction, anxiety and depression. After 8 weeks of paroxetine treatment 
three of the four GHQ-28 subscales showed a significant reduction. Furthermore, the social 
dysfunction subscale showed a significant allele by time interaction. Social dysfunction was 
significantly reduced in A1+ allelic patients compared to those with A1– allelic status. At 
the conclusion of treatment there were no significant differences between these two allelic 
groups in any of the GHQ scores measured. 
 
The potential mechanism of this reduction in social dysfunction may be related to D2 
dopamine receptor physiology. An in vitro study using   3H  spiperone (Noble et al., 1991), 
as a D2 dopamine receptor ligand, found a significant decrease in the number of D2 
dopamine receptors in the brains of subjects with the DRD2 A1+ allele compared to those 
with the A1− allele. An autoradiographic study (Thompson et al., 1997), using   3H  
raclopride as a D2 dopamine receptor ligand, found significantly reduced D2 dopamine 
receptor binding in the brains of A1+ compared with A1− allelic subjects. In vivo positron 
emission tomography (PET) studies, using   [11C] raclopride, found a significant reduction 
in brain D2 dopamine receptor density in healthy subjects with the A1+ allele than subjects 
with the A1− allele (Pohjalainen et al., 1998  ;   Jönsson et al., 1999). Another study           
(Laruelle et al., 1998) determined D2 dopamine receptor binding potential in healthy 
controls and in schizophrenic patients using   [123I] IBZM. No significant difference in this 
combined sample was found in the D2 dopamine receptor binding potential between A1+ 
and A1− allelic subjects. However, when the controls and schizophrenics were separately 
examined, a trend for a lower binding potential was found in A1+ allelic controls, whilst a 
trend for a higher binding potential was noted in A1+ allelic schizophrenics when compared 
to their respective A1− allelic subjects. Since two of the above studies (Pohjalainen et al., 
1998  ;   Laruelle et al., 1998) appeared in the same journal issue, an editorial (Hitzemann, 
1998) reviewed their merits. It suggested that the study using  [123I]  IBZM                
(Laruelle et al., 1998) had insufficient power to detect a significant difference between A1+ 
and A1− allelic controls. Moreover, since schizophrenic patients showed a trend in the 
opposite direction than controls, the results on D2 dopamine receptor binding potential and 
allelic association in schizophrenic subjects may have been confounded by prior neuroleptic 
treatment. Indeed, in a recent PET study (Silvestri et al., 2000) using  [11C] raclopride, 
increased D2 dopamine receptor binding was shown in schizophrenic patients subsequent to 
neuroleptic treatment. 
 
Low D2 dopamine receptor binding is associated with the personality feature of harm 
avoidance (Yasuno et al., 2001) and patients with social phobia have low D2 dopamine 
receptor binding potential (Schneier et al., 2000). Moreover, low D2 dopamine receptor 
density is also associated with depressive personality features (Kestler et al., 2000). Animal 
studies have shown that subordinate female cynomolgus monkeys who are fearful and 
disengaged in social events have decreased D2 dopamine receptor binding and demonstrate 
pathological behaviors suggestive of underlying anxiety (Shively et al., 1997). These human 
and animal studies are consistent with the baseline characteristics of those with the A1 allele 
reporting higher anxiety, social dysfunction and depression. 
 
SSRIs have a significant and complex impact on dopaminergic function but generally have a 
marked inhibitory effect on dopamine release. While stimulation of 5-HT 1A and 5-HT 1B 
receptors facilitate dopamine release, stimulation of 5-HT 2A receptors inhibit dopamine 
release (Ng et al., 1999  ;   Rollema et al., 2000  ;   Gobert et al., 2000). Paroxetine down-
regulates 5 HT 2A receptors in young depressed patients indicating significant agonist 
stimulation (Meyer et al., 2001). In rat studies, fluoxetine administration produces a      60–
70% decrease in extracellular dopamine levels in the caudate putamen, and nucleus 
accumbens (Clark et al., 1996) as well as a 41% reduction in the rat striatum (Yamato et al., 
2001). Decreased mesolimbic dopamine release in subjects taking SSRI antidepressants has 
been linked to the commonly found adverse effects of decreased libido and anorgasmia  
(Hull et al., 1999). SSRI induced increase in extrapyramidal serotonin levels and consequent 
inhibition of the dopaminergic pathways controlling movement has been hypothesized to 
cause SSRI-induced bruxism (Bostwick and Jaffee, 1999). Similarly diminished striatal 
extracellular levels of dopamine and its metabolites have been linked to a parkinsonian 
syndrome induced by sertraline (Di Rocco et al., 1998). Other extrapyramidal reactions 
associated with SSRIs include dystonias, dyskinesias, akathisia, exacerbation of Parkinson’s 
disease and possibly neuroleptic malignant syndrome (Caley,1997). Other effects due to 
diminished dopaminergic neurotransmission include hyperprolactinemia (Goodnick et al., 
2000), galactorrhea (Bonin et al., 1997) as well as breast tenderness and enlargement (Hall, 
1994). 
 
Subjects with low D2 dopamine receptor binding are likely to respond to paroxetine via 
upregulation of mesolimbic D2 dopamine receptors as a consequence of inhibition of 
dopamine release. Therapeutic actions of drugs and their adverse effects are due to 
neurotransmitters activating genes in target neurons (Stahl, 1999). For example, fluoxetine 
causes an increase in nucleus accumbens shell D2 dopamine receptor mRNA resulting in 
increased D2 dopamine receptor postsynaptic binding in the nucleus accumbens (Ainsworth 
et al., 1998). Similarly, the SSRI citalopram increases D2 dopamine receptor mRNA in the 
striatum and nucleus accumbens (Dziedzicka-Wasylewska et al., 1997). This effect of 
citalopram on increased transcription of the D2 dopamine receptor gene is mediated by 
increased serotonin levels induced by SSRIs, as 5-hydroxytryptophan also increases D2 
dopamine receptor mRNA transcription (Kameda et al., 2000). 
 
Increased D2 dopamine receptor gene expression and consequent upregulation of D2 
receptors is likely to be the mechanism by which paroxetine improves social dysfunction. 
Low pretreatment D2 dopamine receptor density may be a requirement for effective 
treatment. Conversely high pretreatment D2 dopamine receptor density may result in a lack 
of improvement in social dysfunction. In a PET study of depressed subjects   [123I] IBZM 
binding was significantly lower in treatment responders at baseline and increased over time. 
Amongst non-responders, baseline IBZM binding was significantly higher (Klimke et al., 
1999). 
 
There are some limitations to this study. The study was an open label trial and hence the 
influence of both patient and clinician expectancy cannot be controlled. However, as both 
patient and clinician were blind to the patient’s DRD2 allelic status, the results are unlikely 
to be biased by expectancy effects. Laboratory staff were also blind to behavioral data until 
after allelic determination for all subjects was completed. The sample size is modest, 
however, the significance of the results indicates a large effect size. The subjects were all 
males and the relevance of the findings to females remains unknown. Equally, these results 
may also generalize to the treatment of other disorders characterised by social dysfunction, 
such as recurrent major depression, social phobia and avoidant personality disorder. 
 
In sum, PTSD patients with the DRD2 A1 allele, in contrast to those without this allele, 
showed a significant positive response to paroxetine treatment with particular respect to 
social dysfunction. The study suggests that the A1 allele may be a useful marker to assist 
clinicians in determining which patients with PTSD are likely to experience improved social 
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